Search

Your search keyword '"Gilbey, E"' showing total 5 results
Start Over Author "Gilbey, E" Publication Year Range Last 50 years
5 results on '"Gilbey, E"'

1. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

Author

Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., Bell, D. R., Bianchi, U., Bolis, G., Brady, M. F., Brodovsky, H. S., Bruckner, H., Buyse, M., Canetta, R., Chylak, V., Cohen, C. J., Colombo, N., Conte, P. F., Crowther, D., Edmonson, J. H., Gennatas, C., Gilbey, E., Gore, M., Guthrie, D., Yeap, B. Y., Aabo, K, Adams, M, Adnitt, P, Alberts, D, Athanazziou, A, Barley, V, Bell, D, Bianchi, U, Bolis, G, Brady, M, Brodovsky, H, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, C, Colombo, N, Conte, P, Crowther, D, Edmonson, J, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, and Yeap, B

Subjects
Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocol, endocrine system diseases, Ovarian Neoplasm, MED/40 - GINECOLOGIA E OSTETRICIA, Antineoplastic Agents, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carboplatin, therapeutic use, Cisplatin, therapeutic use, Female, Humans, Neoplasm Staging, Ovarian Neoplasms, drug therapy/mortality/pathology, Randomized Controlled Trials as Topic, Survival Analysis, Survival Analysis, female genital diseases and pregnancy complications, Carboplatin, Antineoplastic Agent, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Survival Analysi, Cisplatin, Research Article, Randomized Controlled Trials as Topic, Neoplasm Staging, Human
Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients. Images Figure 1 Figure 2 Figure 3

Published
1998

2. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials

Author

Aabo, K, Adams, M, Adnitt, P, Alberts, DS, Athanazziou, A, Barley, V, Bell, DR, Bianchi, U, Bolis, G, Brady, MF, Brodovsky, HS, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, CJ, Colombo, N, Conte, PF, Crowther, D, Edmonson, JH, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Kaye, SB, Laing, AH, Landoni, F, Leonard, RC, Lewis, C, Liu, PY, Mangioni, C, Marsoni, S, Meerpohl, H, Omura, GA, Parmar, MKB, Pater, J, Pecorelli, S, Presti, M, Sauerbrei, W, Skarlos, DV, Smalley, RV, Solomon, HJ, Stewart, LA, Sturgeon, JFG, Tattersall, MHN, Wharton, JT, Ten Bokkel Huinink, WW, Tomirotti, M, Torri, W, Trope, C, Turbow, MM, Vermorken, JB, Webb, MJ, Wilbur, DW, Williams, CJ, Wiltshaw, E, Yeap, BY, Aabo, K, Adams, M, Adnitt, P, Alberts, DS, Athanazziou, A, Barley, V, Bell, DR, Bianchi, U, Bolis, G, Brady, MF, Brodovsky, HS, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, CJ, Colombo, N, Conte, PF, Crowther, D, Edmonson, JH, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Kaye, SB, Laing, AH, Landoni, F, Leonard, RC, Lewis, C, Liu, PY, Mangioni, C, Marsoni, S, Meerpohl, H, Omura, GA, Parmar, MKB, Pater, J, Pecorelli, S, Presti, M, Sauerbrei, W, Skarlos, DV, Smalley, RV, Solomon, HJ, Stewart, LA, Sturgeon, JFG, Tattersall, MHN, Wharton, JT, Ten Bokkel Huinink, WW, Tomirotti, M, Torri, W, Trope, C, Turbow, MM, Vermorken, JB, Webb, MJ, Wilbur, DW, Williams, CJ, Wiltshaw, E, and Yeap, BY

Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.

Published
1998

3. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

Author

Aabo, K, Adams, M, Adnitt, P, Alberts, D, Athanazziou, A, Barley, V, Bell, D, Bianchi, U, Bolis, G, Brady, M, Brodovsky, H, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, C, Colombo, N, Conte, P, Crowther, D, Edmonson, J, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Yeap, B, Alberts, DS, Bell, DR, Brady, MF, Brodovsky, HS, Cohen, CJ, Conte, PF, Edmonson, JH, Yeap, BY, COLOMBO, NICOLETTA, Aabo, K, Adams, M, Adnitt, P, Alberts, D, Athanazziou, A, Barley, V, Bell, D, Bianchi, U, Bolis, G, Brady, M, Brodovsky, H, Bruckner, H, Buyse, M, Canetta, R, Chylak, V, Cohen, C, Colombo, N, Conte, P, Crowther, D, Edmonson, J, Gennatas, C, Gilbey, E, Gore, M, Guthrie, D, Yeap, B, Alberts, DS, Bell, DR, Brady, MF, Brodovsky, HS, Cohen, CJ, Conte, PF, Edmonson, JH, Yeap, BY, and COLOMBO, NICOLETTA

Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.

Published
1998

5. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

Author

Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, and Yeap BY

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, Cisplatin therapeutic use, Female, Humans, Neoplasm Staging, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Randomized Controlled Trials as Topic, Survival Analysis, Antineoplastic Agents therapeutic use, Ovarian Neoplasms drug therapy
Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results